eLabNotebook
> Nucleic Acid Prep &
Purification > Cellular Prep & Analysis > Cell-Based ELISA
Assay PARADIGM Detection Platform
A Novel High-throughput Cell-based ELISA Assay for Screening of Anti-Inflammatory Drugs
Rudolf Lucas1, Christoph Wiesner1, Maren Pflueger1, Barbara Entler1, Rainer Fedra1, Richard Oseghale1, Lore Koller3, Josef Atzler2, Wolfgang Schütt1, Soph Kleber1 and Harald Hundsberger1.
1Medical and Pharmaceutical Biotechnology,Univ. Of Applied Sciences, Krems, Austria;
2Beckman Coulter GmbH, Lagerhausstrasse 45, A-5071 Wals, Austria
3Department of Cell-Biology, University of Salzburg, Salzburg, Austria.
Inflammation is a complex process involving interactions between different cell types and is partially mediated by adhesion molecules. Lung microvascular endothelial cells
(L-MVEC) represent major target cells in diseases associated with lung inflammation, such as Adult Respiratory Distress Syndrome (ARDS). Therefore, the search for novel anti-inflammatory factors acting on these cells is therapeutically promising. To this purpose, we have developed a novel, high-throughput screening assay making use of the PARADIGM™ Detection Platform from Beckman Coulter, for the identification of anti-inflammatory substances acting on human L-MVEC.
* All trademarks are the property of their respective owners. Where applicable, PCR is covered by patents owned by Hoffman-LaRoche Inc.
